2023 Participants

As an independent company active in both human and animal health, Boehringer Ingelheim has learned over generations that the challenging path towards health innovation requires long-term commitment, resilience, and transformative action. Decades of cutting-edge science and innovation has enabled us to deliver many pioneering breakthroughs in some of the most devastating diseases and challenging areas we face globally. Continuing this journey hinges on collaboration.

We believe that working together with our global community of partners brings critical diversity to innovation and accelerates the next breakthroughs in human and animal health that will transform lives now and in generations to come. This collective power, in the tireless pursuit of science and solutions, enables us to build together a healthier, more sustainable, and equitable tomorrow.

GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development. Other assets target other life-threatening disease indications such as cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD)/Organic Acidemias (OA).

Founded in 2012, X’PROCHEM is a CRO (Contract Research Organization) specializied in chemical protein synthesis.

We design and produce therapeutic proteins for our pharmaceutical and biotech partners. We manufacture complex and highly customized proteins up to 400 amino acids (40 kDa) by using an automated process.